Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon May 19, 2013 4:23pm
139 Views
Post# 21415986

RE: RE: RE: 6 weeks, 29 trading days

RE: RE: RE: 6 weeks, 29 trading days

IMO, Dr. Wong and Dr. Nissen are going to reveal something new at their upcoming presentations in 2 weeks. However, my gut feeling is that it is going to only be the teaser SUSTAIN and ASSURE data that may include anything EXCEPT IVUS measurements. We could see data including apoAI, HDL-cholesterol, HDL particle size, and inflammation markers. In this scenario, we probably still won't see IVUS data until end of June. However, how cool would it be for Dr. Wong to present apoAI/HDL values May 30-June 2 at the NLA meeting, and then Dr. Nissen to present the IVUS data June 2-5 at the EAS meeting. That sounds like quite the 1-2 punch!

Bullboard Posts